var data={"title":"Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/243657?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information&quot;</a> and <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249383\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Miltefosine may cause fetal harm. Fetal death and teratogenicity occurred in animals administered miltefosine at doses lower than the recommended human dose. Do not administer miltefosine to pregnant women. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing miltefosine. Advise females of reproductive potential to use effective contraception during therapy and for 5 months after therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502570\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Impavido</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903466\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiparasitic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903483\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-HIV-1 positive patients: Cutaneous, mucosal, visceral: Note: </b> Efficacy is species and locale dependent: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 to 44 kg: 50 mg twice daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;45 kg: 50 mg 3 times daily for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 positive patients (visceral, initial acute infection) (off-label dosing):</b> Oral: 100 mg daily for 28 days (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Free-living amebae (FLA) infections (off-label use) (CDC 2013):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;45 kg: 50 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;45 kg: 50 mg 3 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903482\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis:</b> Children &ge;12 years and Adolescents: Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24255958\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903484\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903485\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22904239\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Impavido: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502569\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815381\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">For the treatment of free-living amebae (FLA) infections, including primary amebic meningoencephalitis (PAM) caused by <i>Naegleria fowleri</i>, granulomatous amebic encephalitis caused by <i>Balamuthia mandrillaris</i>, and <i>Acanthamoeba</i> spp, miltefosine remains available from the CDC through an expanded access investigational new drug protocol (IND) with the FDA. Clinicians who suspect a FLA infection should contact the Centers for Disease Control (CDC) Emergency Operations Center at 770-488-7100 (24 hours/day, 7 days/week).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903463\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Free-living amebae infections:</b> Miltefosine is available in the US directly from the CDC through an expanded access investigational new drug protocol (IND) with the FDA for the treatment of free-living amebae (FLA) infections, including primary amebic meningoencephalitis (PAM) caused by <i>Naegleria fowleri</i>, granulomatous amebic encephalitis caused by <i>Balamuthia mandrillaris</i>, and <i>Acanthamoeba</i> spp. Clinicians who suspect an FLA infection should contact the Centers for Disease Control (CDC) Emergency Operations Center at 770-488-7100 (24 hours/day, 7 days/week). A CDC expert can offer assistance with diagnosis, specimen collection, shipping instructions, and treatment recommendations. Further information is available at <a target=\"_blank\" href=\"http://www.cdc.gov/parasites/naegleria/treatment.html&amp;token=2qlk56F/3K1cx+ynYS5+4qjjQ8xpG0RJ0thFmN+IkBU09Eb11Miii6qNe2tCpWRkLBkuQpgjRnQ0O50WGHZmQw==&amp;TOPIC_ID=91793\" target=\"_blank\">http://www.cdc.gov/parasites/naegleria/treatment.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24151847\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Impavido: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM390972.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WHeLlvW27hVqpt29VHRKVRA==&amp;TOPIC_ID=91793\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM390972.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903486\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Oral: Administer with food to decrease GI distress. Twice daily dosing should be administered with breakfast and dinner; 3 times daily dosing with breakfast, lunch, and dinner.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903468\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis:</b> Treatment of visceral (caused by <i>Leishmania donovani</i>), cutaneous (caused by <i>L. braziliensis</i>, <i>L. guyanensis</i>, and <i>L. panamensis</i>), and mucosal leishmaniasis (caused by <i>L. braziliensis</i>) in adults and adolescents 12 years and older weighing at least 30 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Efficacy of miltefosine in the treatment of other <i>Leishmania</i> species (eg, <i>L. infantum</i>) has not been evaluated; there may be geographic variation in clinical response of the same <i>Leishmania</i> species to miltefosine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469258\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Free-living amebae (FLA) infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22906298\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (28%), dizziness (5% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (36% to 42%), vomiting (28% to 38%), motion sickness (29%), decreased appetite (11% to 23%), diarrhea (8% to 20%), abdominal pain (8% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased platelet count (&lt;150,000: 62%; &lt;50,000: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (&lt;3 x ULN: 94%; 3-5 x ULN: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (&ge;1.5 times above baseline: 10% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (3%), malaise (&le;3%), fatigue (&lt;2%), paresthesia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (5% to 6%), cellulitis (&lt;2%), pyoderma (&lt;2%), skin rash (&lt;2%), Stevens-Johnson syndrome (&lt;2%), urticaria (&lt;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (&lt;2%), constipation (&lt;2%), dysphagia (&lt;2%), flatulence (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Testicular pain (&lt;2%), testicular swelling (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphangitis (6%), anemia (&lt;2%), lymphadenopathy (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess (&lt;2%), ecthyma (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Agranulocytosis, decreased ejaculate volume, dry ejaculation, edema, epistaxis, increased serum bilirubin, jaundice, melena, peripheral edema, scrotal pain, seizure, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903471\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to miltefosine or any component of the formulation; Sjogren-Larsson syndrome; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903472\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Stevens-Johnson syndrome has been reported; discontinue miltefosine if an exfoliative or bullous rash occurs during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility effects: Miltefosine impaired female and male fertility in animals; effects on human fertility have not been adequately studied. Scrotal pain and decreased or absent ejaculation have been reported during miltefosine therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Nausea, vomiting and diarrhea may occur with use; administer with food to decrease GI effects. Ensure adequate fluid intake during therapy to prevent dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: Thrombocytopenia has been reported during therapy for visceral leishmaniasis; monitor platelet count during therapy in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increased liver transaminases and bilirubin have been reported during therapy for visceral leishmaniasis. Assess ALT, AST, and bilirubin during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May increase serum creatinine. Assess kidney function weekly while on therapy and for 4 weeks after the end of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <b>Pregnancy: [US Boxed Warning]: Miltefosine may cause fetal harm; do not administer to pregnant women. Fetal death and teratogenicity occurred in animals at doses lower than the maximum recommended human dose. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing miltefosine. Females of reproductive potential should use effective contraception during miltefosine therapy and for 5 months thereafter;</b> if oral contraceptives are used and nausea, vomiting, and/or diarrhea occur during therapy, additional nonhormonal or alternative methods of effective contraception should be used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23358804\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23358801\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91793&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249400\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249401\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Miltefosine may cause fetal harm; do not administer to pregnant women. Fetal death and teratogenicity occurred in animals at doses lower than the maximum recommended human dose. A pregnancy test (serum or urine) should be obtained in females of reproductive potential prior to prescribing miltefosine. Females of reproductive potential should use effective contraception during therapy and for 5 months after therapy;</b> if oral contraceptives are used and nausea, vomiting, and/or diarrhea occur during therapy, additional nonhormonal or alternative methods of effective contraception should be used.  Untreated  visceral leishmaniasis may be life-threatening to the mother and may result in adverse fetal outcomes (eg, spontaneous abortion, congenital disease due to vertical transmission, small for gestational age newborn, severe anemia); untreated cutaneous leishmaniasis may manifest with larger and atypical appearing lesions and may be associated with adverse fetal outcomes (eg, preterm births, stillbirths). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24249403\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if miltefosine is excreted in breast milk. Due to the potential for serious adverse reactions in the breast-feeding infant, the manufacturer recommends a decision be made whether to discontinue breast-feeding or to discontinue the drug, taking into account the importance of treatment to the mother. The manufacturer also recommends that breast-feeding should be avoided for 5 months after miltefosine therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22904238\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Baseline and as clinically indicated during therapy: liver function tests (AST, ALT, alkaline phosphatase, bilirubin) and BUN/serum creatinine; platelet count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903474\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Exact mechanism unknown; likely interaction with phospholipids and steroids in parasitic cell membranes, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903476\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; phospholipase D-like cleavage of miltefosine releases choline. Fatty alcohol-containing fragment may be oxidized to palmitic acid and undergo fatty acid metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Absolute bioavailability in humans not studied</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: t<sup>1</sup>/<sub>2</sub> alpha: &gt;6 days; t<sup>1</sup>/<sub>2</sub> beta: ~31 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 4 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&lt;0.2% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46817110\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Impavido Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (28): $19,200.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671518\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Impavido (BD, BR, CO, DE, EC, IL, IN, PY);</li>\n      <li>Miltex (AT, BE, BG, BR, CL, CZ, DE, DK, EE, FI, FR, GB, GR, HU, IL, IT, LT, LV, MY, SE, SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aichelburg AC, Walochnik J, Assadian O, et al. Successful treatment of disseminated Acanthamoeba sp infection with miltefosine. <i>Emerg Infect Dis</i>. 2008;14:1743-1746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/18976559/pubmed\" target=\"_blank\" id=\"18976559\">18976559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). <i>Naegleria fowleri</i> &ndash; Primary Amebic Meningoencephalitis (PAM). Available at: <a href=\"http://www.cdc.gov/parasites/naegleria/treatment-hcp.html\" target=\"_blank\">http://www.cdc.gov/parasites/naegleria/treatment-hcp.html</a>. Accessed November 13, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Leishmaniasis- Resources for Health Professionals. Available at: <a href=\"http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl\" target=\"_blank\">http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx-vl</a>. Updated March 20, 2014. Accessed April 4, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dorlo TP, Huitema ADR, Beijnen JH, de Vries PJ. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. <i>Antimicrob Agents Chemother</i>. 2012;56(7):3864-3872.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/22585212/pubmed\" target=\"_blank\" id=\"22585212\">22585212</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Impavido (miltefosine) [prescribing information]. Orlando, FL: Profounda, Inc.; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mart&iacute;nez DY, Seas C, Bravo F, Legua P, Ramos C, Cabello AM, Gotuzzo E. Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. <i>Clin Infect Dis</i>. 2010;51(2):e7-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/20550438/pubmed\" target=\"_blank\" id=\"20550438\">20550438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soto J, Arana A, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. <i>Clin Infect Dis</i>. 2004;38(9):1266-1272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/15127339/pubmed\" target=\"_blank\" id=\"15127339\">15127339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. <i>N Engl J Med</i>. 2002;347(22):1739-1746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/12456849/pubmed\" target=\"_blank\" id=\"12456849\">12456849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed April 8, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Webster D, Umar I, Kolyvas G, et al. Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier. <i>Am J Trop Med Hyg</i>. 2012;87(4):715-718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information/abstract-text/22869634/pubmed\" target=\"_blank\" id=\"22869634\">22869634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO).  Application for inclusion of miltefosine on WHO model list of essential medicines (Paladin Pharmaceuticals).  November, 2010. http://www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf. Accessed April 4, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO).  WHO model list of essential medicines for adults, 18th edition, final amendments, October, 2013. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed April 4, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO).  WHO model list of essential medicines for children, 4th edition, final amendments, October, 2013.  Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed April 4, 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91793 Version 51.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F24249383\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46502570\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F22903466\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F22903483\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F22903482\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F24255958\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22903484\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22903485\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F22904239\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46502569\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F22815381\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F22903463\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F24151847\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22903486\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22903468\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469258\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F22906298\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22903471\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22903472\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23358804\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23358801\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F24249400\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F24249401\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F24249403\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22904238\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22903474\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F22903476\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46817110\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671518\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91793|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Patient drug information</a></li><li><a href=\"topic.htm?path=miltefosine-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-pediatric-drug-information\" class=\"drug drug_pediatric\">Miltefosine (United States: Available via CDC drug service investigational drug [IND] protocol only): Pediatric drug information</a></li></ul></div></div>","javascript":null}